Vigil Neuroscience Launches with $50 Million in Financing to Develop Microglia-based Therapeutics for Neurodegenerative Diseases

Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing. Atlas Venture co-founded, seeded and incubated Vigil with late pre-clinical-stage assets in-licensed from Amgen Inc., who will remain a key shareholder in the company. The Series A round was co-led by Atlas Venture and Northpond Ventures and includes participating investors Hatteras Venture Partners and Alexandria Venture Investments. The company is led by industry veteran Ivana Magovčević-Liebisch, PhD, JD as President and Chief Executive Officer.